Central arterial pressure measurement as a promising method for identifying the initial stage of arterial hypertension


DOI: https://dx.doi.org/10.18565/therapy.2021.2.39-49

Milyagin V.A., Kovaleva O.A., Punin D.A.

Smolensk State Medical University of the Ministry of Healthcare of Russia
Abstract. Aim: to clarify the mechanisms of formation of systolic-diastolic arterial hypertension (SDAH) by measuring central arterial pressure.
Material and methods. We examined 332 people aged 30–60 years: 115 patients with normal blood pressure, 105 with high normal blood pressure and 112 with the first degree of SDAH. All patients underwent applanation tonometry with SphygmoCor device (AtCorMedical, Australia) with the determination of the levels of central blood pressure and indicators reflecting the state of the central hemodynamics.
Results. The measurement of central blood pressure (in the aorta) makes it possible to determine the initial signs of arterial hypertension. An increase in blood pressure to the high normal stage occurs both due to pulse and diastolic blood pressure, and conversion to the SDAH happens due to an increase in diastolic blood pressure in young and middle-aged patients. Augmentation of the diastolic part of the pulse wave along its entire length plays an important role in these processes. An increase in diastolic blood pressure in the early diastole improves heart and other central organs blood supply.
Conclusion. Augmentation of the systolic part of the central pulse wave leads to an isolated increase in central pulse and systolic blood pressure. In the presence of several risk factors for an increase in central pulse wave augmentation (increased arterial stiffness, low height, female sex), an isolated, hidden, central high-risk hypertension can be formed.
Keywords: arterial hypertension, blood pressure, blood pressure augmentation, blood pressure amplification, prehypertension, arterial stiffness
Read entire article

Literature


  1. Баланова Ю.А., Шальнова С.А., Имаева А.Э. с соавт. Распространенность артериальной гипертонии, охват лечением и его эффективность в Российской Федерации (данные наблюдательного исследования ЭССЕ-РФ-2). Рациональная фармакотерапия в кардиологии. 2019; 4: 450–466. [Balanova Yu.A., Shalnova S.A., Imaeva A.E. et al. Prevalence, awareness, treatment and control of hypertension in Russian Federation (Data of observational ESSE-RF-2 study). Ratsional'naya farmakoterapiya v kardiologii = Rational pharmacotherapy in cardiology. 2019; 4: 450–466 (In Russ.)]. doi: https://dx.doi.org/10.20996/1819-6446-2019-15-4-450-466.

  2. Бойцов С.А., Баланова Ю.А., Шальнова С.А. с соавт. Артериальная гипертония среди лиц 25–64 лет: распространенность, осведомленность, лечение и контроль. По материалам исследования ЭССЕ. Кардиоваскулярная терапия и профилактика. 2014; 4: 4–14. [Boytsov S.A., Balanova Yu.A., Shalnova S.A. et al. Arterial hypertension among individuals of 25–64 years old: Prevalence, awareness, treatment and control. By the data from ESSE study. Kardiovaskulyarnaya terapiya i profilaktika = Cardiovascular therapy and prevention. 2014; 4: 4–14 (In Russ.)]. doi: https://dx.doi.org/10.15829/1728-8800-2014-4-4-14.

  3. Ерина А.М., Ротарь О.П., Солнцев В.Н. с соавт. Предгипертензия и факторы риска сердечно-сосудистых заболеваний у жителей Курска. Артериальная гипертензия. 2012; 6: 522–530. [Erina A.M., Rotar O.P., Solntsev V.N. et al. Prehypertension and cardiovascular risk factors in Kursk inhabitants. Arterial’naya gipertenziya =Arterial hypertension. 2012; 6: 522–530 (In Russ.)]. doi: https://dx.doi.org/10.18705/1607-419X-2012-18-6-522-530.

  4. Ерина А.М., Ротарь О.П., Орлов А.В. с соавт. Предгипертензия и кардиометаболические факторы риска (по материалам исследования ЭССЕ-РФ). Артериальная гипертензия. 2017; 3: 243–252. [Erina A.M., Rotar O.P., Orlov A.V. et al. Prehypertension and cardiometabolic risk factors (data of the ESSE-RF study). Arterial’naya gipertenziya =Arterial hypertension. 2017; 3: 243–252 (In Russ.)]. doi: https://dx.doi.org/10.18705/1607-419X-2017-23-3-243-252.

  5. Gryglewska B., Sulicka J., Fornal M. et al. Women with prehypertension in primary care – risk profile on the basis of selected cardiovascular risk factors. Blood Pressure. 2009; 18(3): 99–104. doi: 10.1080/08037050902903447.

  6. Kaplan N.M. Prehypertension: is it relevant for nephrologists? Clin J Am Soc Nephrol. 2009; 4(8): 1381–83. doi: 10.2215/CJN.02340409.

  7. Vasan R.S., Larson M.G., Leip E.P. et al. Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohort study. Lancet. 2001; 358(9294): 1682–86. doi: 10.1016/S0140-6736(01)06710-1.

  8. Whelton P.K., Carey R.M., Aronow W.S. et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: Executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018; 71(6): 1269–324. doi: 10.1161/HYP.0000000000000066.

  9. Nilsson P., Boutouyrie P., Laurent S. Vascular aging a tale of EVA and ADAM in cardiovascular risk assessment and prevention. Hypertension. 2009; 54(1): 3–10. doi: 10.1161/HYPERTENSIONAHA.109.129114.

  10. Бурко Н.В., Авдеева И.В., Олейников В.Э., Бойцов С.А. Концепция раннего сосудистого старения. Рациональная фармакотерапия в кардиологии. 2019; 5: 742–749. [Burko N.V., Avdeeva I.V., Oleynikov V.E., Boicov S.A. The concept of early vascular aging. Ratsional'naya farmakoterapiya v kardiologii = Rational pharmacotherapy in cardiology. 2019; 5: 742–749 (In Russ.)]. doi: https://dx.doi.org/10.20996/1819-6446-2019-15-5-742-749.

  11. Толкунова К.М., Ротарь О.П., Ерина А.М. с соавт. Концепция «супернормального» сосудистого старения – распространенность и детерминанты на популяционном уровне (в рамках ЭССЕ-РФ). Артериальная гипертензия. 2020: 2: 170–183. [Tolkunova K.M., Rotar O.P., Erina A.M. et al. Supernormal vascular aging – prevalence and determinants at population level (the ESSE-RF data). Arterial’naya gipertenziya =Arterial hypertension. 2020: 2: 170–183 (In Russ.)]. doi: https://dx.doi.org/10.18705/1607-419X-2020-26-2-170-183.

  12. Подзолков В.И., Брагина А.Е. Стратегия использования индапамида ретард в профилактике синдрома раннего старения сосудов. Кардиология. 2015; 11: 106–112. [Podzolkov V.I., Bragina A.E. The strategy of indapamide retard use in the prevention of the early vascular aging syndrome. Kardiologiya = Cardiology. 2015; 11: 106–112 (In Russ.)].

  13. Михин В.П., Болдырева Ю.А., Чернятина М.А., Громнацкий Н.И. Состояние параметров жесткости сосудистой стенки у больных артериальной гипертонией на фоне комплексной терапии цитопротекторами и сартанами. Архивъ внутренней медицины. 2015; 5: 40–44. [Mikhin V.P., Boldyreva U.A., Chernyatina M.A., Gromnatsky N.I. State stiffness parameters of the vascular wall in hypertensive patients complex therapy cytoprotector and sartans. Arkhiv vnutrenney meditsiny = Archives of internal medicine. 2015; 5: 40–44 (In Russ.)]. doi: https://dx.doi.org/10.20514/2226-6704-2015-0-5-15.

  14. Федоришина О.В., Протасов К.В., Торунова А.М. Лекарственная коррекция сосудистого ремоделирования у больных артериальной гипертензией: результаты 52-недельного проспективного исследования АРТЕРИЯ-АГ. Рациональная фармакотерапия в кардиологии. 2020; 2: 213–220. [Fedorishina O.V., Protasov K.V., Torunova A.M. Drug correction of vascular remodeling in patients with hypertension: Results of 52-week prospective study ARTERIA-AG. Ratsional'naya farmakoterapiya v kardiologii = Rational pharmacotherapy in cardiology. 2020; 2: 213–220 (In Russ.)]. doi: https://dx.doi.org/10.20996/1819-6446-2020-04-08.

  15. Медик В.А., Токмачев М.С., Фишман Б.Б. Статистика в медицине и биологии. М.: Медицина. 2000; 412 с. [Medik V.A., Tokmachev M.S., Fishman B.B. Statistics in medicine and biology. Moscow: Meditsina = Medicine. 2000; 412 pp. (In Russ.)].

  16. Кушаковский М.С. Эссенциальная гипертензия (гипертоническая болезнь). Причины, механизмы, клиника, лечение. СПб.: Фолиант. 2002; 416 с. [Kushakovskij M.S. Essential hypertension (Hypertension). Ethiology, mechanisms, clinic, treatment. Saint Petersburg: Foliant = Folio. 2002; 416 pp. (In Russ.)].

  17. Hulsen H.T., Nijdam M.E., Bos W.J. et al. Spurious systolic hypertension in young adults; prevalence of high brachial systolic blood pressure and low central pressure and its determinants. J Hypertens. 2006; 24(6): 1027–32. doi: 10.1097/01.hjh.0000226191.36558.9c.

  18. Багаев С.Н., Захаров В.Н., Орлов В.А. с соавт. Регуляция транскапиллярного обмена пульсовым давлением крови. Российский журнал биомеханики. 2008; 3: 7–14. [Bagayev S.N., Zakharov V.N., Orlov V.A. et al. Transcapillary exchange regulation by pulse blood pressure. Rossiyskiy zhurnal biomekhaniki = Russian journal of biomechanics. 2008; 3: 7–14 (In Russ.)].

  19. Ковалева О.А., Милягин В.А. Особенности центральной гемодинамики у молодых мужчин с изолированной систолической артериальной гипертензией. Вестник Смоленской государственной медицинской академии. 2019; 4: 80–88. [Kovaleva O.A., Milyagin V.A. Features of central hemodynamics in young men with isolated systolic arterial hypertension. Vestnik Smolenskoy gosudarstvennoy medicinskoy akademii = Bulletin of the Smolensk State Medical Academy. 2019; 4: 80–88 (In Russ.)].

  20. Кобалава Ж.Д., Котовская Ю.В. Изолированная систолическая артериальная гипертония в различных возрастных группах. Кардиология. 2015; 9: 84–90. [Kobalava Zh.D., Kotovskaya Yu.V. Isolated systolic arterial hypertension in different age groups. Kardiologiya = Cardiology. 2015; 9: 84–90 (In Russ.)].

  21. Peri-Okonny P.A., Patel K.K., Jones P.G. et al. Low diastolic blood pressure is associated with angina in patients with chronic coronary artery disease. J Am Coll Cardiol. 2018; 72(11): 1227–32. doi: 10.1016/j.jacc.2018.05.075.

  22. Messerli F.H., Mancia G., Conti C.R. et al. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med. 2006; 144(12): 884–93. doi: 10.7326/0003-4819-144-12-200606200-00005.

  23. Бойцов С.А. Изучение патогенеза гипертонической болезни продолжается. Терапевтический архив. 2006; 9: 1–12. [Boytsov S.A. The study of the pathogenesis of hypertension is being continued. Terapevticheskiy arkhiv = Therapeutic archive. 2006; 9: 1–12 (In Russ.)].

  24. Cheng H.M., Chuang S.Y., Sung S.H. et al. Derivation and validation of diagnostic thresholds for central blood pressure measurements based on long-term cardiovascular risks. J Am Coll Cardiol. 2013; 62(19): 1780–87. doi: 10.1016/j.jacc.2013.06.029.


About the Autors

Viktor A. Milyagin, MD, professor, head of the Department of therapy, ultrasound and functional diagnostics of Faculty of continuing professional education, Smolensk State Medical University of the Ministry of Healthcare of Russia. Address: 214018, Smolensk, 9 Novo-Kievskaya Str. Tel.: +7 (910) 723-51-57. E-mail: milyagin_va@mail.ru
Olga A. Kovalev, assistant of the Department of therapy, ultrasound and functional diagnostics of Faculty of continuing professional education, Smolensk State Medical University of the Ministry of Healthcare of Russia. Address: 214018, Smolensk, 9 Novo-Kievskaya Str. Tel.: +7 (951) 711-74-97
Denis A. Punin, assistant of the Department of therapy, ultrasound and functional diagnostics of Faculty of continuing professional education, Smolensk State Medical University of the Ministry of Healthcare of Russia. Address: 214018, Smolensk, 9 Novo-Kievskaya Str. Tel.: +7 (951) 700-94-42

Back to Content

Бионика Медиа